Research News

Goserelin reduces ovarian failure associated with breast cancer chemotherapy, study shows

BMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h1274 (Published 09 March 2015) Cite this as: BMJ 2015;350:h1274
  1. Susan Mayor
  1. 1London

Treating women with the gonadotrophin releasing hormone agonist goserelin during chemotherapy for breast cancer significantly reduced the subsequent risk of ovarian failure and improved fertility, an international randomised trial reported in the New England Journal of Medicine has shown.1

The Prevention of Early Menopause Study (POEMS) randomised 257 premenopausal women with operable hormone receptor negative breast cancer to standard chemotherapy either alone …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe